A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Vixotrigine (Primary)
- Indications Trigeminal neuralgia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SURGE
- Sponsors Biogen
- 21 Dec 2018 This trial was suspended in Austria, according to European Clinical Trials Database.
- 19 Dec 2018 Planned End Date changed from 26 Nov 2022 to 7 Aug 2023.
- 19 Dec 2018 Planned primary completion date changed from 26 Nov 2020 to 9 Aug 2022.